Notably, COL6A3 and PRRX1 have been shown to confer resistance to chemotherapeutic agents like cisplatin [50, 51], and circulating COL6A3 has been proposed as a prognostic biomarker for colorectal and breast cancers [52, 53]. Here, PRRX1 is linked to breast carcinoma.